Merck EPS - Earnings per Share 2010-2022 | MRK

Merck annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Merck EPS for the quarter ending June 30, 2022 was $1.55, a 154.1% increase year-over-year.
  • Merck EPS for the twelve months ending June 30, 2022 was $6.53, a 196.82% increase year-over-year.
  • Merck 2021 annual EPS was $5.14, a 84.89% increase from 2020.
  • Merck 2020 annual EPS was $2.78, a 27.03% decline from 2019.
  • Merck 2019 annual EPS was $3.81, a 64.22% increase from 2018.
Merck Annual EPS
2021 $5.14
2020 $2.78
2019 $3.81
2018 $2.32
2017 $0.87
2016 $1.41
2015 $1.56
2014 $4.07
2013 $1.47
2012 $2.00
2011 $2.02
2010 $0.28
2009 $5.65
Merck Quarterly EPS
2022-06-30 $1.55
2022-03-31 $1.70
2021-12-31 $1.48
2021-09-30 $1.80
2021-06-30 $0.61
2021-03-31 $1.25
2020-12-31 $-0.82
2020-09-30 $1.16
2020-06-30 $1.18
2020-03-31 $1.26
2019-12-31 $0.92
2019-09-30 $0.74
2019-06-30 $1.03
2019-03-31 $1.12
2018-12-31 $0.69
2018-09-30 $0.73
2018-06-30 $0.63
2018-03-31 $0.27
2017-12-31 $-0.38
2017-09-30 $-0.02
2017-06-30 $0.71
2017-03-31 $0.56
2016-12-31 $-0.20
2016-09-30 $0.78
2016-06-30 $0.43
2016-03-31 $0.40
2015-12-31 $0.35
2015-09-30 $0.64
2015-06-30 $0.24
2015-03-31 $0.33
2014-12-31 $2.51
2014-09-30 $0.31
2014-06-30 $0.68
2014-03-31 $0.57
2013-12-31 $0.27
2013-09-30 $0.38
2013-06-30 $0.30
2013-03-31 $0.52
2012-12-31 $0.30
2012-09-30 $0.56
2012-06-30 $0.58
2012-03-31 $0.56
2011-12-31 $0.48
2011-09-30 $0.55
2011-06-30 $0.65
2011-03-31 $0.34
2010-12-31 $-0.16
2010-09-30 $0.11
2010-06-30 $0.24
2010-03-31 $0.09
2009-12-31 $2.63
2009-09-30 $1.61
2009-06-30 $0.74
2009-03-31 $0.67
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.318B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17